ArticleBlood cancer journal2025

Bruton's tyrosine kinase inhibition re-sensitizes multidrug-resistant DLBCL tumors driven by BCL10 gain-of-function mutants to venetoclax.

Caroline A Coughlin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.